Ozkiris Abdullah, Evereklioglu Cem, Esel Duygu, Akgün Hülya, Göktas Sertan, Erkiliç Kuddusi
Department of Ophthalmology, Erciyes University Medical Faculty, Kayseri, Turkey.
Curr Eye Res. 2005 Jan;30(1):13-9. doi: 10.1080/02713680490894180.
To investigate the efficacy of intravitreal piperacillin/tazobactam (250 microg/0.1 ml) in the treatment of experimental Pseudomonas aeruginosa endophthalmitis in rabbits.
Twenty New Zealand White albino rabbits were used in this study. The rabbits were divided into two groups (10 rabbits in each), and the right eyes were treated with 0.1 ml intravitreal injections of P. aeruginosa suspension (ATCC 27853, 2 x 10(4) CFU); the left eyes served as uninfected control and were injected with 0.1 ml of saline solution. The right eyes of rabbits in group 1 (n = 10) received intravitreal injection of 250 microg piperacillin/tazobactam 24 h after intravitreal inoculation of P. aeruginosa. Group 2 eyes (n = 10) received no treatment and served as infected controls. Clinical examination of the eyes in each group was performed on the first, third, and sixth day after the inoculation of P. aeruginosa. After the last ophthalmic examination, 0.1 ml vitreous aspirates were obtained for microbiological analysis, and then the eyes were enucleated for histopathological evaluation.
The mean clinical scores of group 1 and group 2 at the first day after P. aeruginosa inoculation were similar (p > 0.05). At the sixth day, the mean clinical score of group 1 was significantly lower when compared with group 2 eyes (p < 0.001). Microbiological analysis revealed that group 2 had a significantly more cfu/ml than group 1 (p < 0.001), and the mean histopathological score of group 2 was significantly higher than group 2 (p = 0.009).
Intravitreal application of 250 microg/0.1 ml piperacillin/tazobactam seems to be effective in the treatment of P. aeruginosa endophthalmitis in rabbits. Intravitreal piperacillin/tazobactam combination may be a new therapy for P. aeruginosa endophthalmitis.
研究玻璃体内注射哌拉西林/他唑巴坦（250微克/0.1毫升）治疗兔实验性铜绿假单胞菌性眼内炎的疗效。
本研究使用20只新西兰白兔。将兔子分为两组（每组10只），右眼玻璃体内注射铜绿假单胞菌悬液（ATCC 27853，2×10⁴CFU）0.1毫升；左眼作为未感染对照，注射0.1毫升生理盐水。第1组（n = 10）兔子的右眼在玻璃体内接种铜绿假单胞菌24小时后接受玻璃体内注射250微克哌拉西林/他唑巴坦。第2组眼睛（n = 10）不接受治疗，作为感染对照。在接种铜绿假单胞菌后的第1、3和6天对每组眼睛进行临床检查。在最后一次眼科检查后，抽取0.1毫升玻璃体进行微生物学分析，然后摘除眼球进行组织病理学评估。
铜绿假单胞菌接种后第1天，第1组和第2组的平均临床评分相似（p>0.05）。第６天，第1组的平均临床评分与第2组眼睛相比显著降低（p<0.001）。微生物学分析显示，第2组的每毫升菌落形成单位数明显多于第1组（p<0.001），第2组的平均组织病理学评分显著高于第1组（p = 0.009）。
玻璃体内应用250微克/0.1毫升哌拉西林/他唑巴坦似乎对治疗兔铜绿假单胞菌性眼内炎有效。玻璃体内注射哌拉西林/他唑巴坦联合用药可能是治疗铜绿假单胞菌性眼内炎的一种新疗法。
